Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for Evernorth’s employer and health plan clients.

Cigna now offers employers $200 Wegovy, Zepbound copay option. The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients; The company hopes the new discount, which caps monthly out-of-pocket ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Another study from the Evernorth Research Institute, as reported by Reuters, ... The spike in teen prescriptions comes after Wegovy was approved for adolescents in late 2022.

In 2023, the rate of first-time Wegovy prescriptions was 9.9 per 100,000 adolescents. That figure rose to 14.8 per 100,000 in 2024 — a 50% increase. First-time Saxenda prescriptions remained ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.